FluMist is the first vaccine to prevent influenza that does not need to be administered by a healthcare provider, the ...

AstraZeneca has just scored big on the quest to make routine vaccinations less of a hassle. | The FDA signed off on ...

The U.S. FDA has given the green light for AstraZeneca's FluMist nasal spray vaccine to be self-administered or administered ...

The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's nasal spray flu vaccine for ...

Iskra Reic, Executive Vice President, Vaccines and Immune Therapies, AstraZeneca, said: “The approval of FLUMIST for self-administration is an important step forward in making vaccines more accessible ...

FluMist is a nasally-administered influenza vaccine that is indicated for active immunization to prevent influenza disease in individuals 2 to 49 years of age.

The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's influenza nasal spray vaccine for ...

AstraZeneca has shared an early look at the performance of its in-house antibody-drug conjugate (ADC) technology, publishing phase 1 data on candidates that could compete with molecules from ...

The applause mentioned above was for AstraZeneca’s Phase 3 NIAGARA study in bladder cancer, which showed that giving patients the checkpoint inhibitor Imfinzi — both before and after surgery ...

AstraZeneca's FluMist influenza vaccine, which can be self-administered. Experts hope an option for at-home flu vaccination ...

British pharma giant AstraZeneca plans to spend $135 million to expand the manufacturing operations footprint of its site in Södertälje, Sweden, by 50%. The project calls for a 2,700-square ...

AstraZeneca Plc shares are on track for their biggest weekly decline since July 2023, after a disappointing update for the British drugmaker’s experimental lung cancer medicine with partner ...